In this episode of The Issue, CEO of Life Biosciences Jerry McLaughlin joins hosts Sanjay D’Souza, PhD and Jason West, PhD for a discussion on how epigenetic reprogramming could restore function in aging and injured cells. He explains the science behind ER-100, an investigational gene therapy now in a Phase 1 trial for optic neuropathies, and explores the broader promise of targeting age-related diseases to help improve quality of life.

Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/ 

In this episode of&nbsp;The Issue, CEO of Life Biosciences Jerry McLaughlin joins hosts Sanjay D&rsquo;Souza, PhD and Jason West, PhD for a discussion on how epigenetic reprogramming could restore function in aging and injured cells. He explains the science behind ER-100, an investigational gene therapy now in a Phase 1 trial for optic neuropathies, and explores the broader promise of targeting age-related diseases to help improve quality of life.
Music: &lsquo;Bright New Morning&rsquo; by Steven O&rsquo;Brien &ndash; released under CC-BY 4.0. <a href="https://www.steven-obrien.net/">https://www.steven-obrien.net/</a>&nbsp;

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.